Virbac SA VIRP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 22.14
- Price/Sales
- 2.46
- Dividend Yield (Trailing)
- 0.34%
- Dividend Yield (Forward)
- 0.34%
- Total Yield
- 0.94%
Company Profile
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, followed by Asia and Latin America.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 5,500
- Website
- https://www.virbac.com
Comparables
Valuation
|
Metric
|
VIRP
|
ELIS
|
WLN
|
|---|---|---|---|
Price/Earnings (Normalized) | 22.14 | 10.32 | 3.24 |
Price/Book Value | 3.30 | 1.33 | 0.23 |
Price/Sales | 2.46 | 1.14 | 0.41 |
Price/Cash Flow | 16.25 | 3.91 | 2.45 |
Price/Earnings
VIRP
ELIS
WLN
Financial Strength
|
Metric
|
VIRP
|
ELIS
|
WLN
|
|---|---|---|---|
Quick Ratio | 0.85 | 0.66 | 0.79 |
Current Ratio | 1.65 | 0.74 | 1.04 |
Interest Coverage | 19.56 | 3.12 | −19.59 |
Quick Ratio
VIRP
ELIS
WLN
Profitability
|
Metric
|
VIRP
|
ELIS
|
WLN
|
|---|---|---|---|
Return on Assets (Normalized) | 8.91% | 3.46% | 2.25% |
Return on Equity (Normalized) | 14.90% | 9.31% | 5.53% |
Return on Invested Capital (Normalized) | 12.07% | 5.34% | 3.63% |
Return on Assets
VIRP
ELIS
WLN
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Hwtpjnxjf | Frxl | $790.4 Bil | |||
| Johnson & Johnson
JNJ
| Thskwtffv | Fmmv | $388.5 Bil | |||
| AbbVie Inc
ABBV
| Vjczrzdk | Ycwmf | $344.1 Bil | |||
| Merck & Co Inc
MRK
| Jfwhnnzq | Ypv | $288.2 Bil | |||
| Roche Holding AG ADR
RHHBY
| Rcrgqckcmc | Bjyz | $258.7 Bil | |||
| AstraZeneca PLC ADR
AZN
| Fpkdykjf | Pdst | $242.3 Bil | |||
| Novartis AG ADR
NVS
| Pzjhksxw | Wxrg | $234.2 Bil | |||
| Amgen Inc
AMGN
| Rgnhrcdxt | Lwkf | $173.4 Bil | |||
| Pfizer Inc
PFE
| Cwwtfcj | Lcr | $164.8 Bil | |||
| Sanofi SA ADR
SNY
| Nrktnnyx | Gfqmg | $144.3 Bil |
United States